Document is current
Any future updates will be listed below
-
Authors
Yadav, Monika
Sharma, Akansha
Patne, Ketki
Tabasum, Saba
Suryavanshi, Jyoti
Rawat, Laxminarayan
Machaalani, Marc https://orcid.org/0000-0002-6708-9922
Eid, Marc
Singh, Rana P.
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
Pal, Soumitro
Sabarwal, Akash https://orcid.org/0000-0003-1760-4903
-
Funding
Funding for this research was provided by:
Dana-Farber/Harvard Cancer Center (5P50CA101942-18, 2P50CA101942-16 and 5P30CA006516-56)
M K Bhan YRFP, Department of Biotechnology, Ministry of Science and Technology
MacNaught Fellowship
The Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI
Foundation for the National Institutes of Health (RO1 CA193675 and RO1 CA222355)
- License Information
-
More Information
Article History
Received: 22 July 2024
Revised: 2 November 2024
Accepted: 19 December 2024
First Online: 10 February 2025
Competing interests
: Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria past 5 years, ongoing or not, from: Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work; Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA; Equity: Tempest, Pionyr, Osel, PrecedeBio, CureResponse, InnDura Therapeutics, Primium; Committees: NCCN, GU Steering Committee, ASCO (BOD 6-2024-, ESMO, ACCRU, KidneyCan; Medical writing and editorial assistance support may have been funded by Communications companies in part; No speaker’s bureau; Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components; The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter.
